Effects of alpha-2-adrenoceptor agonism and antagonism on equine blood insulin and glucose concentrations after oral carbohydrate load.
Authors: Hallman I A M, Raekallio M R, Koho N, Weckman M J, Karikoski N P
Journal: Veterinary journal (London, England : 1997)
Summary
# Editorial Summary: Alpha-2-Adrenoceptor Modulation and Equine Glucose-Insulin Dynamics Detomidine, widely used for equine sedation, produces significant metabolic side-effects including reduced insulin secretion and elevated blood glucose—effects that may complicate management of metabolically compromised horses. Researchers administered four treatments (saline control, detomidine alone at 0.02 mg/kg, the peripheral alpha-2 antagonist vatinoxan at 0.2 mg/kg, and detomidine combined with vatinoxan) to 16 horses in a randomised cross-over design, with all animals receiving an oral carbohydrate challenge (corn syrup at 0.45 mL/kg) and blood sampling over six hours. Detomidine substantially suppressed insulin responses, with nadir concentrations of 3.7 µIU/mL compared with saline controls at 17.4 µIU/mL, whilst simultaneously driving blood glucose to a peak of 13.0 mmol/L versus 8.7 mmol/L in controls; crucially, co-administration of vatinoxan reversed these detomidine-induced changes, normalising both metrics. The practical implications merit consideration: vatinoxan warrants investigation as a potential adjunct when detomidine sedation is necessary in insulin-dysregulated horses, though the authors appropriately acknowledge the need for further research before clinical recommendations can be confidently established.
Read the full abstract on PubMed
Practical Takeaways
- •Detomidine sedation causes significant metabolic disruption (low insulin, high glucose) after eating, which may be clinically relevant in horses with metabolic disease; consider this when sedating horses for procedures
- •Vatinoxan (a peripheral alpha-2 antagonist) can reverse detomidine's metabolic effects without compromising sedation—useful option for metabolically compromised horses requiring sedation
- •If using detomidine in horses with insulin dysregulation or laminitis risk, be aware of the temporary hyperglycaemic response and consider withholding feed or using vatinoxan co-administration
Key Findings
- •Detomidine significantly reduced insulin concentration (median nadir 3.7 µIU/mL) compared to saline (17.4 µIU/mL) after oral carbohydrate load (P<0.0001)
- •Detomidine significantly increased blood glucose (peak 130.5 mmol/L) compared to saline (8.7 mmol/L) and detomidine+vatinoxan (8.5 mmol/L) (P<0.0001)
- •Vatinoxan co-administration alleviated detomidine-induced hyperglycaemia and hypoinsulinaemia, reducing peak glucose to 7.6 mmol/L
- •Vatinoxan alone reduced blood glucose and delayed insulin responses to carbohydrates compared to saline (P=0.02)